JP2020105223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020105223A5 JP2020105223A5 JP2020066723A JP2020066723A JP2020105223A5 JP 2020105223 A5 JP2020105223 A5 JP 2020105223A5 JP 2020066723 A JP2020066723 A JP 2020066723A JP 2020066723 A JP2020066723 A JP 2020066723A JP 2020105223 A5 JP2020105223 A5 JP 2020105223A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- administration
- composition according
- therapy
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 claims 19
- 108010050904 Interferons Proteins 0.000 claims 19
- 229940079322 interferon Drugs 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000011200 topical administration Methods 0.000 claims 4
- 238000011319 anticancer therapy Methods 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 238000005507 spraying Methods 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 238000001815 biotherapy Methods 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 210000004876 tela submucosa Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 238000010317 ablation therapy Methods 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749570P | 2013-01-07 | 2013-01-07 | |
| US61/749,570 | 2013-01-07 | ||
| US201361779711P | 2013-03-13 | 2013-03-13 | |
| US61/779,711 | 2013-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551117A Division JP2016508987A (ja) | 2013-01-07 | 2014-01-07 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020105223A JP2020105223A (ja) | 2020-07-09 |
| JP2020105223A5 true JP2020105223A5 (enExample) | 2020-09-24 |
Family
ID=51062515
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551117A Pending JP2016508987A (ja) | 2013-01-07 | 2014-01-07 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2015551113A Pending JP2016506413A (ja) | 2013-01-07 | 2014-01-07 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2019190263A Pending JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2020066723A Pending JP2020105223A (ja) | 2013-01-07 | 2020-04-02 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2021200049A Pending JP2022031331A (ja) | 2013-01-07 | 2021-12-09 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551117A Pending JP2016508987A (ja) | 2013-01-07 | 2014-01-07 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2015551113A Pending JP2016506413A (ja) | 2013-01-07 | 2014-01-07 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2019190263A Pending JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200049A Pending JP2022031331A (ja) | 2013-01-07 | 2021-12-09 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20160022778A1 (enExample) |
| EP (3) | EP2941266B1 (enExample) |
| JP (5) | JP2016508987A (enExample) |
| KR (4) | KR20210069127A (enExample) |
| CN (2) | CN104902917A (enExample) |
| AU (2) | AU2014204386B2 (enExample) |
| CA (2) | CA2897335A1 (enExample) |
| HK (2) | HK1216394A1 (enExample) |
| TW (3) | TWI718086B (enExample) |
| WO (2) | WO2014106459A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| CN107847564B (zh) * | 2015-05-12 | 2021-11-09 | 远东超级实验室有限公司 | 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途 |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CN108721603B (zh) * | 2017-04-14 | 2020-11-13 | 中国医学科学院基础医学研究所 | 干扰素α-1a在制备用于治疗癌症的药物中的用途 |
| KR101880015B1 (ko) * | 2017-12-08 | 2018-07-19 | 아주대학교산학협력단 | 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물 |
| WO2020112991A1 (en) * | 2018-11-27 | 2020-06-04 | The Children's Hospital Of Philadelphia | Compositions and methods for treating cancer |
| US20220251605A1 (en) * | 2019-06-14 | 2022-08-11 | The Brigham And Women's Hospital, Inc. | Membrane attack complexes and uses thereof |
| CN111658779A (zh) * | 2020-06-22 | 2020-09-15 | 四川大学华西医院 | 治疗新型冠状病毒肺炎的联合用药物 |
| WO2022156735A1 (zh) * | 2021-01-21 | 2022-07-28 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的癌症治疗方法和药物组合 |
| US11759434B2 (en) * | 2022-02-03 | 2023-09-19 | Sytheon Limited | Methods and compositions for treating melanoma and non-melanoma skin cancers |
| CN114533706B (zh) * | 2022-02-15 | 2022-10-14 | 深圳市利云德生物技术有限公司 | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 |
| WO2024076973A1 (en) * | 2022-10-04 | 2024-04-11 | Brown University | Compositions and methods of delivering large proteins |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005169A (en) * | 1932-08-27 | 1935-06-18 | Rowe Andrew Reed | Casting metal ingots |
| US4672108A (en) | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4681930A (en) | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
| PL172758B1 (pl) | 1992-10-19 | 1997-11-28 | Dura Pharma Inc | Inhalator do proszków suchych PL PL PL PL PL PL PL |
| AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
| US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
| WO1995017901A1 (en) * | 1993-12-29 | 1995-07-06 | Matrix Pharmaceutical, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| EP0861321B1 (en) | 1995-10-13 | 2006-05-31 | President And Fellows Of Harvard College | Phosphopantetheinyl transferases and uses thereof |
| GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
| US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| US6065472A (en) | 1996-01-03 | 2000-05-23 | Glaxo Wellcome Inc. | Multidose powder inhalation device |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
| US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
| CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
| US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
| JP3983985B2 (ja) * | 2000-03-22 | 2007-09-26 | 株式会社東芝 | ＭｘＡタンパク質の多型遺伝子およびその使用 |
| IL155741A0 (en) | 2000-11-03 | 2003-12-23 | Pbl Biomedical Lab | Interferons, uses and compositions related thereto |
| US8551469B2 (en) * | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
| CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
| FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| CN1375502A (zh) | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
| US8158145B2 (en) | 2002-02-19 | 2012-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous absorption type plaster |
| WO2004091571A2 (en) | 2003-04-08 | 2004-10-28 | New Jersey Institute Of Technology (Njit) | Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| MY141751A (en) * | 2003-08-28 | 2010-06-30 | Sichuan Biotechnology Res Ct | Recombinant super-compound interferon |
| US7585647B2 (en) * | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| ES2473622T3 (es) * | 2003-08-28 | 2014-07-07 | Superlab Far East Limited | Usos de interferones con estructura espacial alterada |
| WO2005021777A2 (en) | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
| CN1910195A (zh) * | 2003-08-28 | 2007-02-07 | 辉阳科技美国公司 | 通过空间构象调节蛋白质功能 |
| FR2862541B1 (fr) * | 2003-11-21 | 2007-04-20 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques |
| WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
| US20080102114A1 (en) * | 2004-04-23 | 2008-05-01 | Panduranga Rao Koritala | Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents |
| CN1740197B (zh) | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
| EP1868636A4 (en) * | 2005-03-09 | 2012-03-28 | Guangwen Wei | USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| WO2006133088A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US8071125B2 (en) | 2005-12-09 | 2011-12-06 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Transdermal patch containing isosorbide dinitrate and bisoprolol |
| EP2056883B1 (en) | 2006-08-04 | 2021-09-22 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US8095213B1 (en) | 2007-05-31 | 2012-01-10 | Purdue Pharma L.P. | Transdermal patch |
| ES2336873B1 (es) * | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| EP2413901A4 (en) * | 2009-03-30 | 2015-05-06 | Cerulean Pharma Inc | POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES |
| EP2239580B1 (en) | 2009-04-09 | 2013-03-27 | Lga Biotecnologie Srl | Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis |
| CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| CA2812644A1 (en) | 2010-09-27 | 2012-04-05 | Zestagen, S.A. | Compositions and methods for treating neoplasia |
| US9107887B2 (en) * | 2011-03-10 | 2015-08-18 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| US20130184437A9 (en) | 2011-06-08 | 2013-07-18 | Guangwen Wei | Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| US20130273527A1 (en) * | 2012-04-13 | 2013-10-17 | Superlab Far East Limited | Method for inducing cell senescence by recombinant interferon with altered spatial configuration |
| AU2013293049A1 (en) * | 2012-07-20 | 2015-02-26 | La Trobe University | Method of diagnosis and treatment |
| TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| KR102230547B1 (ko) | 2013-11-13 | 2021-03-22 | 수퍼랩 파 이스트 리미티드 | 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도 |
-
2014
- 2014-01-06 TW TW103100472A patent/TWI718086B/zh not_active IP Right Cessation
- 2014-01-06 TW TW103100470A patent/TW201427681A/zh unknown
- 2014-01-06 TW TW108107884A patent/TWI726291B/zh active
- 2014-01-07 HK HK16104396.4A patent/HK1216394A1/zh unknown
- 2014-01-07 KR KR1020217016953A patent/KR20210069127A/ko not_active Ceased
- 2014-01-07 CN CN201480003935.3A patent/CN104902917A/zh active Pending
- 2014-01-07 KR KR1020157021423A patent/KR20150139824A/ko not_active Ceased
- 2014-01-07 US US14/759,410 patent/US20160022778A1/en not_active Abandoned
- 2014-01-07 WO PCT/CN2014/000019 patent/WO2014106459A2/en not_active Ceased
- 2014-01-07 EP EP14735273.6A patent/EP2941266B1/en active Active
- 2014-01-07 KR KR1020157021350A patent/KR20150103284A/ko not_active Ceased
- 2014-01-07 CA CA2897335A patent/CA2897335A1/en not_active Abandoned
- 2014-01-07 US US14/759,483 patent/US20150352188A1/en not_active Abandoned
- 2014-01-07 HK HK16102577.9A patent/HK1214528A1/zh unknown
- 2014-01-07 AU AU2014204386A patent/AU2014204386B2/en active Active
- 2014-01-07 CN CN201480003898.6A patent/CN104994866A/zh active Pending
- 2014-01-07 CA CA2897312A patent/CA2897312C/en active Active
- 2014-01-07 JP JP2015551117A patent/JP2016508987A/ja active Pending
- 2014-01-07 JP JP2015551113A patent/JP2016506413A/ja active Pending
- 2014-01-07 EP EP14735427.8A patent/EP2941264B1/en active Active
- 2014-01-07 WO PCT/CN2014/070212 patent/WO2014106492A2/en not_active Ceased
- 2014-01-07 KR KR1020217018383A patent/KR20210077005A/ko not_active Ceased
- 2014-01-07 AU AU2014204368A patent/AU2014204368B2/en active Active
- 2014-01-07 EP EP21161499.5A patent/EP3895725A3/en active Pending
-
2018
- 2018-07-18 US US16/038,704 patent/US20180326012A1/en not_active Abandoned
- 2018-07-25 US US16/044,582 patent/US10874716B2/en active Active
-
2019
- 2019-10-17 JP JP2019190263A patent/JP2020023547A/ja active Pending
-
2020
- 2020-04-02 JP JP2020066723A patent/JP2020105223A/ja active Pending
- 2020-12-29 US US17/136,656 patent/US12109250B2/en active Active
-
2021
- 2021-12-09 JP JP2021200049A patent/JP2022031331A/ja active Pending
- 2021-12-13 US US17/548,598 patent/US20220339255A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020105223A5 (enExample) | ||
| JP2016508987A5 (enExample) | ||
| JP2022031331A (ja) | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 | |
| CN103083239A (zh) | 一种蟾毒灵脂质体及其制备方法和应用 | |
| WO2017162055A1 (zh) | 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用 | |
| CN101744842A (zh) | 脂质体中药贴膜 | |
| CN102370987B (zh) | 一种包载抗肿瘤药物组合物的注射用脂质体 | |
| JP2011500011A (ja) | 癌治療用の組合せ製品 | |
| CN111346081A (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| CN1997383B (zh) | 含水母发光蛋白的组合物及使用它的方法 | |
| CN101623286B (zh) | 包含葫芦素类活性成分的经皮给药组合物 | |
| CN102247335B (zh) | 一种蟾毒灵干粉吸入剂及其制备方法、应用 | |
| CN102302475B (zh) | 一种脂蟾毒配基干粉吸入剂及其制备方法、应用 | |
| CN102961409B (zh) | 一种蟾皮提取物干粉吸入剂 | |
| CN109498547B (zh) | 一种平阳霉素局部注射制剂及其制备方法 | |
| CN115634215B (zh) | 水热响应微针贴片及其制备方法和应用 | |
| Starr | Innovations in drug delivery. | |
| CN107375299A (zh) | 一种积雪草酸的新用途及含积雪草酸的抗肿瘤药物组合 | |
| CN102247336B (zh) | 一种蟾蜍噻咛干粉吸入剂及其制备方法、应用 | |
| CN103071159B (zh) | 一种阿霉素-多肽复合物、药物组合物的制备方法和应用 | |
| CN111249300B (zh) | 褪黑素联合甲钴胺在治疗糖尿病创面愈合障碍中的应用 | |
| WO2014137050A1 (ko) | 트레일이 표면 수식되고 화학 항암제가 봉입된 다공성 마이크로입자 및 이의 제조방법 | |
| Chen et al. | Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer | |
| Gorabi et al. | Microneedles in antiparasitic drug delivery applications | |
| CN101856359A (zh) | 一种抗急性髓系白血病的药物组合物 |